Enhanced Safety Surveillance of Influenza Vaccines in General Practice, Winter 2015-16: Feasibility Study

Journals

1. Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Human Vaccines & Immunotherapeutics 2019;15(11):2624 View
2. Dos Santos G, Nguyen B, Damaso S, Godderis L, Martínez-Gómez X, Eckermann T, Loos H, Salamanca de la Cueva I, Shende V, Schmidt A, Yeakey A. Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season. Drug Safety 2020;43(3):265 View
3. Dos Santos G, Shende V, Damaso S, Yeakey A. Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis. Advances in Therapy 2019;36(12):3340 View
4. Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, Eckermann T, Godderis L, Martínez Gómez X, Godard E, Soler M, Yousefi M, Salamanca de la Cueva I, Nwoji U. Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season. Infectious Diseases and Therapy 2022;11(1):463 View
5. Moeller-Arendt M, van de Witte S, Nauta J, de Voogd H, Rogoll J, Nisslein T. Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons. Vaccine 2023;41(2):606 View
6. Salamanca de la Cueva I, Cinconze E, Eckermann T, Nwoji U, Godderis L, Lu E, Martínez-Gómez X, Wang H, Yanni E. Safety Profile of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season. Drug Safety 2021;44(12):1375 View
7. Dos Santos G, Eckermann T, Martínez‐Gómez X, Parra J, Nwoji U, Salamanca de la Cueva I. Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient‐reported outcome system for vaccine safety remote monitoring. Influenza and Other Respiratory Viruses 2023;17(3) View
8. Cocco N, Leibundgut G, Pelliccia F, Cammalleri V, Nusca A, Mangiacapra F, Cocco G, Fanale V, Ussia G, Grigioni F. Arrhythmias after COVID-19 Vaccination: Have We Left All Stones Unturned?. International Journal of Molecular Sciences 2023;24(12):10405 View
9. Dos Santos G, Devadiga R, Kim C, Bang J. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014–2022) Following the Introduction of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Drug Safety 2024;47(4):365 View
10. Dos Santos G, Yeakey A, Shende V, Smith K, Lin F, Zandman-van-Dijk E, Damaso S, Schmidt A. Passive enhanced safety surveillance of GSK’s quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season. BMJ Open 2019;9(8):e028043 View
11. de la Cueva I, Gerber J, Hastie A, Brotons C, Panzer F, Pirçon J, Talsma P, Eckermann T, Nikic V, Gomez X, Alsdurf H. Enhanced Safety Surveillance of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season. Drug Safety 2024 View